WHO and ASCO formalize a global cancer care alliance
WHO has formalized a collaboration with the American Society of Clinical Oncology, joining the world’s leading public health institution with one of the largest physician and oncology professional organizations. The agreement is aimed at a blunt and urgent problem: cancer is a leading cause of morbidity and mortality worldwide, and families in low- and middle-income countries carry the heaviest burden when high-quality care remains out of reach.
The partnership is built around a simple clinical premise. Access to care is not enough if the care itself is inconsistent, unsafe, or disconnected from evidence. In too many settings, late diagnosis, weak treatment infrastructure, limited specialty training, and poor accountability combine to produce avoidable harm long before survival statistics are even discussed.
Workforce training aims to expand oncology capacity
Capacity building sits at the center of the agreement. WHO and ASCO plan to use virtual and in-person education to strengthen core competencies in cancer care, drawing on ASCO’s existing Global Courses and adapting them to country-specific needs in consultation with WHO Member States.
The practical value of this approach is immediate. Oncology systems fail when too few clinicians can safely deliver systemic therapy, interpret pathology, manage toxicities, or coordinate multidisciplinary care. Training the workforce is therefore not an abstract academic exercise; it is a prerequisite for diagnosing cancer accurately, choosing appropriate treatment, and preventing preventable complications from becoming fatal.
Virtual platforms can extend reach across large geographies, while in-person training can anchor mentorship, hands-on skills, and local implementation. The agreement places emphasis on tailoring education to each country’s context, a critical detail in cancer care, where the most useful intervention in one setting may be infrastructure support, while another may need expertise in supportive care, treatment protocols, or referral pathways.
Trial access and research capacity are part of the same problem
The collaboration also targets access to clinical trials. WHO and ASCO will work with Member States to align research priorities with national cancer burdens and local realities, while developing virtual forums and training opportunities to strengthen clinical trial capability and regional collaboration.
This matters because trial access is often concentrated in a small number of well-resourced centers, leaving many patients excluded from studies that shape modern cancer care. When trial populations do not reflect the geography and disease burden of the wider world, evidence can become less portable to the places where the need is greatest. Expanding trial infrastructure in lower-resource settings can help close that gap, while also building local research expertise and improving the relevance of future oncology evidence.
The focus on research alignment also carries policy significance. National cancer burdens differ widely, and trial agendas that ignore those differences can miss the cancers, stages, and treatment barriers that drive the greatest harm. Linking research planning to actual population needs gives governments and clinicians a better chance of producing data that can be acted on locally.
Quality and accountability are being treated as clinical priorities
One of the most consequential elements of the agreement is the emphasis on quality, accessibility, and accountability at the facility level. WHO will contribute experience supporting national cancer programmes, while ASCO will bring quality care certification and training expertise to help deliver programs where they are likely to have the greatest impact.
Cancer care can look active on paper and still fail in practice. A patient may receive a diagnosis, chemotherapy, surgery, or radiation and yet still experience unsafe delivery, delayed treatment, poor symptom control, or fragmented follow-up. Quality standards matter because treatment intensity alone does not determine outcomes; execution does. Safe infusion practices, timely pathology, reliable referral systems, and evidence-based supportive care are all part of cancer treatment, not optional add-ons.
This is especially relevant in settings where low-quality care causes avoidable harm. The partnership explicitly frames quality as a core requirement rather than a secondary aspiration, and that framing changes how governments and health systems may evaluate cancer services. If care is not measurable, accountable, and aligned with evidence, then survival gains remain fragile.
No one should have to question whether cancer treatment is safe and effective.
What this partnership means for patients and health systems
The agreement carries weight because it links global health leadership with disease-specific expertise. WHO can help mobilize governments and integrate cancer priorities into public health systems; ASCO can contribute clinical education, professional standards, and oncology-specific quality tools. Together, they are aiming to support health professionals, guide policy, and strengthen programs that improve access and survival.
Dr Julie R. Gralow, ASCO’s chief medical officer and executive vice president, described the collaboration as a framework for strengthening the oncology workforce, supporting research, and bringing evidence-based care to diverse resource settings. Dr André Ilbawi of WHO’s Cancer Programme said low-quality care causes avoidable harm and that care must meet the standards patients deserve.
The agreement does not provide a new drug, device, or trial result. Its significance lies elsewhere: in the operational machinery that determines whether cancer medicine reaches patients safely and at scale. Workforce capacity, research access, and facility quality are the pressure points that shape outcomes in everyday oncology practice, especially where resources are limited and the stakes are high.
The next test will be implementation at country level, where training programs, trial infrastructure, and quality initiatives will need to be adapted to local systems rather than applied as a one-size-fits-all model. That is where the partnership will either translate into measurable clinical benefit or remain an ambitious policy commitment.